Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

While the broader stock market suffered steep losses amid trade policy shifts select health technology equities stood out.

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

Looking to upgrade your wellness habits? Wellness Social Club has landed in Melbourne, and brings celebrity-tier treatments ...

If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...